4 unknown, 2 not yet recruiting, 2 terminated, 1 suspended. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Not yet recruiting 2, Terminated 2, Suspended 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Borderline Resectable Pancreatic Cancer: new trials by email Literature Review of Borderline Resectable Pancreatic Cancer trials Research Report on Borderline Resectable Pancreatic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) Gemcitabine Delivered by Transarterial Microperfusion - Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Vermont | 10 | 2026-12-01 | 2026-03-17 |
| Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy, Gemcitabine plus Capecitabine, Modified FOLFIRINOX - Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 56 | 2026-09-01 | 2026-09-22 |
| Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer irinotecan liposome II combined with 5-FU/LV and oxaliplatin - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 45 | 2024-04-17 | 2024-07-10 |
| NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2024-03-10 | 2024-04-03 |
| Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Drug GC4711, Placebo - SBRT, Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Galera Therapeutics, Inc. | 177 | 2021-05-07 | 2024-05-21 |
| IORT on Borderline Resectable Pancreatic Cancer Intraoperative radiotherapy - Borderline Resectable Pancreatic Cancer | Phase 2 | Suspended | Universita di Verona | 100 | 2019-10-01 | 2024-05-07 |
| Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer nab-paclitaxel and S-1 - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2019-05-01 | 2020-03-10 |
| Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer FOLFIRINOX, gemcitabine + nab-paclitaxel - Borderline Resectable Pancreatic Cancer | Phase 2 | Unknown | Nagoya University | 50 | 2015-07-01 | 2020-09-10 |
| Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer gemcitabine/nab-paclitaxel, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer | Phase 2 | Terminated | Nathan Bahary, MD | 2 | 2014-12-01 | 2018-07-26 |
Pancreatic Neoplasms (3) · Neoplasms (1)
Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Pancreatic Diseases (3)
Gemcitabine (3) · Oxaliplatin (3) · 130-nm albumin-bound paclitaxel (2) · Fluorouracil (2) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Irinotecan (1) · Leucovorin (1) · S 1 (combination) (1) · Surgical Procedures, Operative (1) · camrelizumab (1) · folfirinox (1) · irinotecan sucrosofate (1) · surufatinib (1)
Peking Union Medical College Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Galera Therapeutics, Inc. (1) · Nagoya University (1) · Nathan Bahary, MD (1) · Shanghai Zhongshan Hospital (1) · Universita di Verona (1) · University of Vermont (1)
China (4) · United States (3) · Canada (1) · France (1) · Italy (1) · United Kingdom (1)
PMID 24006012, PMID 24635869, PMID 28069018, PMID 29800971, PMID 33593311, PMID 34145168, PMID 38039992, PMID 38264869